Vivacta bio
vivacta-bio.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Latest round
Series A
Apr 2026 · 5 mo ago
Backers
1
OrbiMed
The money's age
Fresh money
5 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 29
Raised a round Series A
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Apr 2026 | — | — | morningstar.com |
Backed byfrom the funds' portfolios and accelerator catalogs
OrbiMed Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
CREATE Medicines is pioneering in vivo immune cell programming with RNA powered, LNP delivered CAR therapies – unlocking scalable…
DeepEn One™ in vivo Microendoscopy Platform. Single-Fibre Endoscope for High-Resolution In Vivo Bioimaging.
Etherna pioneers in mRNA-LNP platforms, offering custom drug delivery platforms for tailored and innovative LNP drug delivery solutions.
Manifold Bio has built the first high-throughput in vivo (HTV) discovery engine—combining massively multiplexed in vivo screening and…
PIRAMIDAL. Bridge in-vivo with in-silico intelligence.
Vivo: the solution for the overwhelming amount of data in clinical trials.
Overview
微滔生物成立于2025年6月25日，其前身系沙砾集团为自主研发的体内CAR-T平台独立运营而成。微滔生物将基于T 靶向 LNP 递送系统开发in vivo CAR-T管线，专注于非病毒体内靶向细胞治疗业务，该业务主要用于血液瘤及自身免疫疾病治疗。.
News
Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million
Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta" or "Vivacta Bio"), an innovative biotechnology company focused on revolutionizing in vivo CAR-T therapies, announces the company recently completed Series A and Series A+ financing of over US$ 50 milli
Read more
Report
Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin
Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA-based in v
Read more
Report
Financials
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2026 | — | Details |